Biomea FusionBMEA
About: Biomea Fusion Inc is a preclinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of irreversible small molecule drugs to treat patients with genetically defined cancers. The company's product candidate, BMF-219, is designed to be an orally bioavailable, potent and selective irreversible inhibitor of menin, an important transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers.
Employees: 107
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
574% more call options, than puts
Call options by funds: $28.9M | Put options by funds: $4.28M
119% more capital invested
Capital invested by funds: $108M [Q2] → $235M (+$128M) [Q3]
0% more funds holding in top 10
Funds holding in top 10: 1 [Q2] → 1 (+0) [Q3]
4% less repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 28
2.13% less ownership
Funds ownership: 66.5% [Q2] → 64.37% (-2.13%) [Q3]
18% less funds holding
Funds holding: 105 [Q2] → 86 (-19) [Q3]
57% less first-time investments, than exits
New positions opened: 13 | Existing positions closed: 30
Research analyst outlook
5 Wall Street Analysts provided 1 year price targets over the past 3 months
5 analyst ratings
D. Boral Capital Jason Kolbert 41% 1-year accuracy 67 / 162 met price target | 2,898%upside $128 | Buy Maintained | 10 Jan 2025 |
HC Wainwright & Co. Joseph Pantginis 31% 1-year accuracy 121 / 386 met price target | 837%upside $40 | Buy Reiterated | 18 Dec 2024 |
Piper Sandler Joseph Catanzaro 29% 1-year accuracy 9 / 31 met price target | 345%upside $19 | Overweight Maintained | 31 Oct 2024 |
EF Hutton Jason Kolbert 41% 1-year accuracy 67 / 162 met price target | 2,898%upside $128 | Buy Maintained | 31 Oct 2024 |
Barclays Peter Lawson 12% 1-year accuracy 3 / 26 met price target | 158%upside $11 | Equal-Weight Maintained | 30 Oct 2024 |
Financial journalist opinion
Based on 4 articles about BMEA published over the past 30 days